These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16413684)

  • 1. Gene-hypermutated isoforms of MYC protein: Tumour-suppressor P-53 protective-initiation of apoptosis that normally prevents Burkitt's lymphoma tumorigenesis can be enhanced.
    Wiseman A
    Med Hypotheses; 2006; 66(5):1046-7. PubMed ID: 16413684
    [No Abstract]   [Full Text] [Related]  

  • 2. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
    Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
    Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.
    Habel ME; Lemieux R; Jung D
    J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing a conditional box II-deleted Myc protein.
    Fest T; Guffei A; Williams G; Silva S; Mai S
    Oncogene; 2005 Apr; 24(18):2944-53. PubMed ID: 15735723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer: two in one.
    Berns A
    Nature; 2005 Aug; 436(7052):787-9. PubMed ID: 16094355
    [No Abstract]   [Full Text] [Related]  

  • 6. c-myc Suppression in Burkitt's lymphoma cells.
    Simonsson T; Henriksson M
    Biochem Biophys Res Commun; 2002 Jan; 290(1):11-5. PubMed ID: 11779125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
    Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
    Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of apoptosis-regulating proteins in Burkitt's lymphomas.
    Pagnano KB; Silva MD; Vassallo J; Souza MS; Costa FF; Saad ST
    Haematologica; 2002 Mar; 87(3):ELT16. PubMed ID: 11869962
    [No Abstract]   [Full Text] [Related]  

  • 9. Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
    Suk FM; Lin SY; Lin RJ; Hsine YH; Liao YJ; Fang SU; Liang YC
    Oncotarget; 2015 Sep; 6(28):25988-6001. PubMed ID: 26317903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The great MYC escape in tumorigenesis.
    Dang CV; O'donnell KA; Juopperi T
    Cancer Cell; 2005 Sep; 8(3):177-8. PubMed ID: 16169462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term follow-up of c-myc, p53 and proliferation measurements in malignant melanoma.
    Ross DA; Laing JH; Sanders R; Wilson GD
    Eur J Surg Oncol; 2006 Feb; 32(1):80-4. PubMed ID: 16256294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis.
    Cardone M; Kandilci A; Carella C; Nilsson JA; Brennan JA; Sirma S; Ozbek U; Boyd K; Cleveland JL; Grosveld GC
    Mol Cell Biol; 2005 Mar; 25(6):2395-405. PubMed ID: 15743832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
    Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
    J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Myc over-expression in Ramos Burkitt's lymphoma cell line predisposes to iron homeostasis disruption in vitro.
    Habel ME; Jung D
    Biochem Biophys Res Commun; 2006 Mar; 341(4):1309-16. PubMed ID: 16466700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli.
    Kuttler F; Amé P; Clark H; Haughey C; Mougin C; Cahn JY; Dang CV; Raffeld M; Fest T
    Oncogene; 2001 Sep; 20(42):6084-94. PubMed ID: 11593416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the therapeutic efficacy of p53 restoration in tumors.
    Martins CP; Brown-Swigart L; Evan GI
    Cell; 2006 Dec; 127(7):1323-34. PubMed ID: 17182091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma.
    Hartleben G; Müller C; Krämer A; Schimmel H; Zidek LM; Dornblut C; Winkler R; Eichwald S; Kortman G; Kosan C; Kluiver J; Petersen I; van den Berg A; Wang ZQ; Calkhoven CF
    EMBO J; 2018 Nov; 37(21):. PubMed ID: 30237309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer regression by senescence.
    Serrano M
    N Engl J Med; 2007 May; 356(19):1996-7. PubMed ID: 17494935
    [No Abstract]   [Full Text] [Related]  

  • 19. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells.
    Gregory MA; Hann SR
    Mol Cell Biol; 2000 Apr; 20(7):2423-35. PubMed ID: 10713166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging molecular networks in Burkitt's lymphoma.
    Mangani D; Roberti A; Rizzolio F; Giordano A
    J Cell Biochem; 2013 Jan; 114(1):35-8. PubMed ID: 22903691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.